구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab) Chia Tai Tianqing Pharmaceutical G…·RAS/BRAF Wild Type Colorectal Canc… 1 trials |
|---|---|
Overview Program | TQB2922 injection+TAS-102 tablets ± Bevacizumab |
Overview Company | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | RAS/BRAF Wild Type Colorectal Cancer |
Overview Indication | RAS/BRAF Wild Type Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A case report of insulin autoimmune syndrome induced by drugs for colorectal cancer.. Insulin autoimmune syndrome (IAS) is a rare autoimmune endocrine disease. At present, there are no recognized guidelines. We present a case study of a colorectal cancer patient who was diagnosed with IAS following standard postoperative adjuvant chemotherapy. After comprehensive intervention with glucose suppleme… |
Clinical Safety signal | A case report of insulin autoimmune syndrome induced by drugs for colorectal cancer.. Insulin autoimmune syndrome (IAS) is a rare autoimmune endocrine disease. At present, there are no recognized guidelines. We present a case study of a colorectal cancer patient who was diagnosed with IAS following standard postoperative adjuvant chemotherapy. After comprehensive intervention with glucose suppleme… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab) Chia Tai Tianqing Pharmaceutical G…·RAS/BRAF Wild Type Colorectal Canc… 1 trials |
|---|---|
Overview Program | TQB2922 injection+TAS-102 tablets ± Bevacizumab |
Overview Company | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | RAS/BRAF Wild Type Colorectal Cancer |
Overview Indication | RAS/BRAF Wild Type Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A case report of insulin autoimmune syndrome induced by drugs for colorectal cancer.. Insulin autoimmune syndrome (IAS) is a rare autoimmune endocrine disease. At present, there are no recognized guidelines. We present a case study of a colorectal cancer patient who was diagnosed with IAS following standard postoperative adjuvant chemotherapy. After comprehensive intervention with glucose suppleme… |
Clinical Safety signal | A case report of insulin autoimmune syndrome induced by drugs for colorectal cancer.. Insulin autoimmune syndrome (IAS) is a rare autoimmune endocrine disease. At present, there are no recognized guidelines. We present a case study of a colorectal cancer patient who was diagnosed with IAS following standard postoperative adjuvant chemotherapy. After comprehensive intervention with glucose suppleme… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교